טוען...

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Metformin is considered to be one of the most effective therapeutics for the treatment of type 2 diabetes (T2D) since it specifically reduces hepatic gluconeogenesis without increasing insulin secretion, inducing weight gain, or posing a risk of hypoglycemia(1,2). For over half a century, this agent...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	Madiraju, Anila K., Erion, Derek M., Rahimi, Yasmeen, Zhang, Xian-Man, Braddock, Demetrios, Albright, Ronald A., Prigaro, Brett J., Wood, John L., Bhanot, Sanjay, MacDonald, Michael J., Jurczak, Michael, Camporez, Joao-Paulo, Lee, Hui-Young, Cline, Gary W., Samuel, Varman T., Kibbey, Richard G., Shulman, Gerald I.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	2014
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4074244/ https://ncbi.nlm.nih.gov/pubmed/24847880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature13270
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

פריטים דומים